ReviewCurrent opinion in rheumatology2020
Management of systemic sclerosis: the first five years.
Review in Current opinion in rheumatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.
- B-cell centrality dictates therapeutic efficacy across autoimmune diseases: a systematic review.Frontiers in immunology · 2026Pooled it
- Effects of a Resilience-Building Energy Management Program on Fatigue and Other Symptoms in Systemic Sclerosis: A Randomized Controlled Trial.Arthritis care & research · 2024Trial
- Tocilizumab Prevents Progression of Early Systemic Sclerosis-Associated Interstitial Lung Disease.Arthritis & rheumatology (Hoboken, N.J.) · 2021Trial
- Effectiveness and Impact on Quality of Life of a Hand Rehabilitation Program in Longstanding Systemic Sclerosis: A Prospective, Non-Randomized, Controlled Pilot Study.Journal of clinical medicine · 2026Article
- Available Biomarkers for Personalized Prognostication in Early and Very Early Systemic Sclerosis: A Narrative Review of the Current Literature.Journal of personalized medicine · 2026Review
- Association between myocardial involvement and subclinical left ventricular dysfunction in patients with systemic sclerosis: a cardiac magnetic resonance study.Quantitative imaging in medicine and surgery · 2026Article
- 'It helps me stay on track': patient experiences using a mobile app for self-management of systemic sclerosis with a focus on fatigue in women.Rheumatology advances in practice · 2026Article
- Systemic sclerosis-associated interstitial lung disease: How to manage in 2024?Rheumatology and immunology research · 2024Article
- Anti-Th/To Antibodies in Scleroderma: Good Prognosis or Serious Concern?Journal of clinical medicine · 2024Review
- Experiences of systemic sclerosis patients with home monitoring of their pulmonary function: a qualitative study.Rheumatology advances in practice · 2024Article
- Impact of a resilience-building energy management intervention for people with systemic sclerosis: a mixed methods study.Rheumatology advances in practice · 2024Article
- Immune Profiling of Patients with Systemic Sclerosis through Targeted Proteomic Analysis.International journal of molecular sciences · 2023Article
- A Multidisciplinary Approach as a Goal for the Management of Complications in Systemic Scleroderma: A Literature Review and Case Scenario.Diagnostics (Basel, Switzerland) · 2023Review
- The Impact of Progressive Pulmonary Fibrosis in Systemic Sclerosis-Associated Interstitial Lung Disease.Journal of clinical medicine · 2023Review
- Risk factors for lung function decline in systemic sclerosis-associated interstitial lung disease in a large single-centre cohort.Rheumatology (Oxford, England) · 2023Article
- Therapeutic Approaches to Systemic Sclerosis: Recent Approvals and Future Candidate Therapies.Clinical reviews in allergy & immunology · 2023Review
- Systemic sclerosis associated interstitial lung disease: a conceptual framework for subclinical, clinical and progressive disease.Rheumatology (Oxford, England) · 2023Article
- [The impact of COVID-19 in a cohort of patients with systemic sclerosis].Revista medica del Instituto Mexicano del Seguro Social · 2023Article
- Common mental disorders in South Asian patients with systemic sclerosis: a CIS-R-based cross-sectional study.Rheumatology international · 2022Article
- Kidney Involvement in Systemic Sclerosis.Journal of personalized medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
purpose of reviewThis review provides a risk-stratified and evidence-based management for subsets of systemic sclerosis (SSc) patients in the first five years from disease onset. RECENT
findingsCardiopulmonary disease remains the primary cause of mortality in SSc patients. Morbidity and mortality in SSc-associated pulmonary arterial hypertension have improved with combination treatment, in either an upfront or sequential treatment pattern. Traditional therapies for interstitial lung disease (SSc-ILD) have targeted those with clinically significant and progressive ILD with immunosuppression. New data suggest a possible paradigm shift, introducing immunosuppressive therapy to patients before they develop clinically significant or progressive ILD. The year 2019 saw the approval of the first FDA-approved therapy for SSc-associated interstitial lung disease, using an antifibrotic agent previously approved for idiopathic pulmonary fibrosis. To date, only autologous hematopoietic stem cell transplant has demonstrated a mortality benefit for SSc-ILD, albeit in a narrow spectrum of SSc-ILD patients. SUMMARY: SSc is a highly heterogeneous autoimmune disease typified by varying clinical trajectories. Its management may be stratified within the first five years by subclassifying patients based on factors that have important prognostic significance: skin distribution and autoantibody status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.